UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATIONTransaction Agreement • September 3rd, 2024 • Recursion Pharmaceuticals, Inc. • Biological products, (no disgnostic substances)
On August 8, 2024, Recursion Pharmaceuticals, Inc. (“Recursion”) entered into a transaction agreement (the “Transaction Agreement”) with Exscientia plc (“Exscientia”) to acquire the entire issued and to be issued share capital of Exscientia pursuant to a scheme of arrangement (the “Scheme of Arrangement”) under Part 26 of the United Kingdom Companies Act 2006 (the “proposed Transaction”).
